Efsitora
-
Efsitora Alfa (Lilly’s Once-Weekly Insulin) Shows A1C Reduction and Safety Profile Comparable to Daily Insulin in Phase 3 Trials
Lilly announced positive Phase 3 trial results for once-weekly insulin efsitora alfa (efsitora) in adults with type 2 diabetes. The QWINT-1, QWINT-3, and QWINT-4 trials demonstrated non-inferior A1C reduction compared to daily basal insulin. The company plans to submit efsitora for regulatory review by the end of the year.
